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Although earlier, seminal studies dem-
onstrated that the gut per se has the
intrinsic ability to regulate the rates of
iron absorption, the spotlight in the past
decade has been placed on the systemic
regulation of iron homeostasis by the
hepatic hormone hepcidin and the mo-
lecular mechanisms that regulate its
expression. Recently, however, attention
has returned to the gut based on the
finding that hypoxia inducible factor-2
(HIF-2a) regulates the expression of key
genes that contribute to iron absorption.
Here we review the current understand-
ing of the molecular mechanisms that
regulate iron homeostasis in the gut by
focusing on the role of HIF-2 under
physiological steady-state conditions
and in the pathogenesis of iron-related
diseases. We also discuss implications
for adapting HIF-2–based therapeutic
strategies in iron-related pathological
conditions. (Blood. 2013;122(6):885-892)
Introduction
Iron (Fe) is an essential nutrient required in many cellular
biosynthetic and metabolic processes such as heme and sulfur-iron
cluster biosynthesis, oxygen transport, mitochondrial respiration, and
DNA replication.1 The body of a healthy human male contains;4 g
of total iron, which is in a dynamic equilibrium between different
tissues: 1 g is predominantly stored in hepatocytes, whereas 65% to
80% of total iron trafﬁcs in a closed circuit in which erythrophago-
cytosis of senescent red blood cells by reticuloendothelial macro-
phages in the spleen enables iron to be returned to the bone marrow
for incorporation into new erythrocytes. Approximately 1 mg of
dietary iron is absorbed daily at the proximal duodenum, a process
that is essential in order to replace daily losses due to limited blood
losses, desquamation, and so forth.2 Excess iron accumulation and the
resulting production of reactive oxygen species through the Fenton/
Haber Weiss reaction are involved in the pathogenesis of iron-
overload–related diseases including hereditary hemochromatosis (HH)
and b-thalassemia.
Iron absorption is increased during iron deﬁciency and
decreased upon iron loading.2 This inverse relationship depends
on a network of signals, which reﬂect systemic body iron re-
quirements and the interaction of these signals with the enterocyte
iron sensing and transport machinery. Iron homeostasis is
regulated systemically by the hormone hepcidin, a 25-amino-
acid peptide produced mainly by the hepatocytes. Hepcidin expression
is increased by iron loading and inﬂammatory signals and is
attenuated by iron deﬁciency, anemia, increased erythropoietic
activity, and hypoxia.3 Hepcidin inhibits iron absorption and iron
recycling by binding to the only known iron exporter, ferroportin
(FPN).4 Recent advances in the understanding of the regulation of
hepcidin expression and the mechanism of hepcidin action have
been detailed elsewhere.3
Here, we review current knowledge regarding the roles of hypoxia
inducible factor-2 (HIF-2) and iron regulatory proteins 1 (IRP1) and
2 (IRP2) in the molecular circuitry that regulates iron absorption
by enterocytes. We also discuss recent ﬁndings demonstrating the
importance of IRP1-dependent regulation of HIF-2 in the regulation
of iron homeostasis and implications in the context of iron-related
pathophysiological conditions.
Key molecules regulating iron homeostasis in
the gut
Dietary iron is broadly classiﬁed into 2 categories based on chemical
form. The majority of iron is nonheme iron, which is present in most
foods, including cereal, vegetables, and meat. It is found in ferritin
(Ft) and other proteins, as well as several nonprotein-bound forms.5
Iron that is present in heme is mainly found in meat.
The solubility of ferric salts or nonheme iron is highly dependent
on a variety of intraluminal parameters, including pH.6 In the presence
of reductive factors or reductases, ferric iron (Fe31) is reduced to the
ferrous (Fe21) form at the brush border membrane. Duodenal cyto-
chrome b561 (DCYTB), a diheme-containing and ascorbate-
dependent ferric enzyme, has been proposed to mediate this reductive
event in the duodenum.7 While Dcytb knockout mice display no overt
defects in iron homeostasis when subjected to iron-rich or iron-
deﬁcient diets,8 they have less nonheme iron in the spleen and
signiﬁcantly lower reticulocyte mean corpuscular hemoglobin when
compared with control mice.9 Ferric reductases belonging to the Steap
family also have been proposed to act at the brush border membrane.10
Fe21 can be transported via divalent metal-ion transporter 1
(DMT1/NRAMP2).11 DMT1 is a proton-coupled metal transporter
of a broad range of divalent ions, although Fe21 is its principal
physiological substrate. The importance of duodenal DMT1 in Fe21
transport is underscored by the anemic phenotype of Dmt1 intestinal
knockout mutants.12 Mutations of DMT1 in humans result in
hypochromic microcytic anemia that may13 or may not14 be accom-
panied by massive hepatic iron overload.
Iron absorbed by mature enterocytes is either stored in Ft or
exported across the basolateral enterocyte membrane into the plasma
by FPN.15 Ft is a globular protein composed of both H (FtH) and
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L (FtL) subunits. FtH possesses ferroxidase activity and has been
shown, in addition to its iron storage function, to play an active role in
iron export.16
Accordingly, Fpn deletion in the murine intestine results in
enterocyte iron overload and neonatal lethality.17 FPN exports
Fe21; the release of iron from FPN is coupled to the actions of
copper-dependent ferroxidases, primarily the transmembrane protein
hephaestin (HEPH).18 HEPH catalyzes the oxidation of Fe12 to
Fe13, which is subsequently bound to transferrin. Disruption of
HEPH activity (eg, due to copper deﬁciency or mutation, as in the
sex-linked anemiamouse) results in iron sequestration in enterocytes,
conﬁrming its key role in iron export across the enterocyte basolateral
membrane.19
Free heme is highly insoluble due to its hydrophobic porphyrin
ring. However, heme can be complexed to a number of chelators
(including arginate and albumin) and preferentially absorbed in
duodenum as the intestinal pH 5.5 to 6 favors its solubility.20 Heme
carrier protein 1 has been proposed as an intestinal heme transporter,
but in vivo studies indicate that heme carrier protein 1 functions
predominantly as a folate transporter.21 Therefore, the mechanism of
heme uptake by enterocytes remains unresolved. HRG-1 is another
heme transporter,22 for which an essential role for macrophage heme-
iron recycling has been recently demonstrated.23 HRG-1 may poten-
tially function as a heme transporter in the intestine. Heme is
catabolized by heme-oxygenase into Fe21 bilirubin and carbon
monoxide. Feline leukemia virus subgroup C cellular receptor is
a transmembrane heme exporter that plays a key role in eryth-
ropoiesis by exporting excess heme from maturing erythroblasts
in humans.24 Feline leukemia virus subgroup C cellular receptor
is also abundantly expressed in the duodenum, but its speciﬁc
role in heme export from enterocytes has not been addressed.
Systemic vs local regulation of iron
absorption in the gut
Iron absorption is increased under conditions of iron deﬁciency,
increased erythropoietic drive, and hypoxia and is decreased by iron
loading and inﬂammation. Expression of the key proteins involved
in iron absorption is controlled at multiple levels: transcriptional,
posttranscriptional, and posttranslational. The different steps of the
iron absorption process may be subject to distinct cell-autonomous
mechanisms and/or systemic regulation by hepcidin.
The majority of the body’s daily iron consumption is used to meet
the needs of erythropoiesis. In settings of increased erythropoietic
demand, intestinal iron absorption increases to meet the marrow’s
needs for additional iron. Increased erythropoietic activity in the bone
marrow is observed in different forms of anemia ranging from iron-
deﬁciency anemia to hereditary forms characterized by ineffective
erythropoiesis, such as b-thalassemia. Prolonged exposure to a hyp-
oxic environment in humans, as well as experimental hypoxia and
anemia induced by phlebotomy/hemolysis in mouse models, is also
characterized by an increased erythropoietic demand and results in an
increase in iron absorption rates.25-27
Systemic regulation of iron absorption by hepcidin
Increased iron absorption correlates with elevated expression of
DMT1, DCYTB, and FPN at the messenger RNA (mRNA) and
protein level.7,11,28,29 Hepatic hepcidin expression is inversely
correlated with the duodenal expression of iron transporters and iron
absorption rates in various mouse models of hepcidin overexpression
and deﬁciency.30-32 The established view is that plasma hepcidin
inhibits iron efﬂux into plasma by directly binding to and thereby
inducing the degradation of FPN, which is located on enterocytes and
macrophages. However, data on the precise molecular actions of
hepcidin on FPN in the gut are less clear.29,33-35
Some reports have suggested that hepcidin also may reduce iron
absorption by decreasing the expression of enterocyte DMT1,
either at the transcription level34 or through ubiquitin-dependent
proteasomal degradation.35 The Nedd4 interacting protein 1
(NDFP1) and 2 (NDFP2) adaptor proteins have been reported to
regulate DMT1 in vitro via ubiquitination by WW domain contain-
ing E3 ubiquitin protein ligase 2 (WWP2) and neural precursor cell
expressed developmentally down-regulated 4-like E3 ubiquitin protein
ligase (NEDD4L or NEDD4-2) in Chinese hamster ovary cells.36
The involvement of this NDFIPs-WWP2 pathway in the hepcidin-
mediated degradation of DMT1 remains to be demonstrated.
Local regulation of iron absorption in enterocytes
Although it is widely recognized that low liver hepcidin expression
contributes to the upregulated expression of iron transporters during
iron deﬁciency, in vitro evidence has suggested that the upregulated
expression of iron transporters that occurs following exposure to
desferroxamine, an iron chelator, occurs in a cell-autonomous
manner.28 Cell-autonomous regulation of duodenal iron absorption
in response to hypoxia has also been well documented. Early ex-
perimental evidence supported the notion that acute hypoxia affects
apical iron uptake independently of systemic cues such as eryth-
ropoietic drive or hepcidin levels: increased apical iron uptake was
observed in rats as early as 6 to 8 hours after initiation of
hypoxia.37,38 This early induction precedes changes in circulating
iron levels or erythropoiesis37,38 or a decrease in hepcidin occurring
only after at least 24 hours of hypoxia in mice39 and in humans.40,41
In addition, this hypoxic response increased iron absorption but was
independent of dietary or mucosal iron status.42
Althoughtheeffectof increasederythropoiesisonironabsorptionhas
generally been attributed to the strong downregulation of hepcidin
expression, a direct effect of erythropoietin (EPO) on duodenal
enterocytes has been recently proposed.Srai et al43 suggested thatEPO
acts directly on duodenal enterocytes through its receptor EPO-R to
upregulate expression of iron transporters, based on ﬁndings in a
nephrectomized rat model of chronic renal failure.Whether thismech-
anism is relevant in human pathological conditions characterized by
ineffective erythropoiesis (such asb-thalassemia), or inmurine experi-
mentalmodels of hypoxia or anemia characterized by high erythropoi-
etic demand and iron absorption rates, remains to be established.
While iron deﬁciency and hypoxia promote iron absorption, oral
administration of large doses of iron attenuates the subsequent ab-
sorption of smaller doses of iron administered hours later. This effect
has been attributed to decreases in transcript and protein levels of
both DCYTB and DMT1, which occur as early as 6 hours post iron
administration, but not to changes in the expression of FPN or
HEPH.44 These ﬁndings indicate that local enterocyte iron levels can
directly regulate the apical membrane phase of iron transport.
Transcriptional regulation by HIF-2
The transcriptional regulation of genes involved in apical iron uptake
and mucosal iron transfer was largely unknown until the recent
discovery of the involvement of HIF-2 transcription factor in this
process. The HIF transcription factors are central mediators of cellular
adaptation to hypoxia.45 HIF is a heterodimer, and its expression is
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principally regulated by oxygen. The HIF heterodimer consists of
2 helix-loop-helix proteins: an a-regulatory subunit, which is the
oxygen- and iron-responsive component, and the b-subunit, also
known as the aryl hydrocarbon receptor nuclear translocator, which is
constitutively expressed. Three regulatory HIF subunits have been
cloned and named HIF-1a, HIF-2a, and HIF-3a. To date, HIF-1a
has been the most extensively studied. In the presence of oxygen, the
hydroxylation of HIF-a at conserved proline residues within the
oxygen-dependent degradation domain is the rate-limiting step for
subsequent HIF-a protein degradation and is catalyzed by prolyl-4-
hydroxylase domain enzymes (PHDs).46 Three PHD isoforms exist in
mammals and are encoded by different genes: PHD1 (also known as
egg laying defective gene [EGL] 9 homolog [EGLN] 2 or HIF prolyl
hydroxylase [HPH] 3), PHD2 (EGLN1 or HPH2), and PHD3
(EGLN3 or HPH1). PHDs are iron- and 2-oxoglutarate–dependent
dioxygenases utilizing O2 as a substrate, 2-oxoglutarate as a cosub-
strate, and iron (Fe21) and ascorbate as cofactors. The 4-hydroxypro-
lines are subsequently recognized by the protein von Hippel–Lindau
(pVHL) E3 ubiquitin ligase, which targets HIF-a for degradation
by the 26S proteasome through polyubiquitination by the E3-
ubiquitin-ligase complex containing elongin B and C, cullin-2, and
rbx1.47
Factor inhibiting HIF is another 2-oxoglutarate–dependent dioxy-
genase that hydroxylates a conserved asparagine residue within the
C-terminal transactivation domain of HIF1-a and HIF2- a.48
Asparagine hydroxylation impairs interaction of HIF-a with the
transcriptional coactivators p300 and CREB-binding protein and
therefore inhibits transcriptional activity.49 HIF-1a is probably the
preferentially targeted a-isoform.49 When O2 is scarce, or under
iron-deﬁcient conditions, the activities of PHD and factor inhibiting
HIF are inhibited, thus enabling HIF-a to escape degradation and
translocate to the nucleus where it dimerizes with the constitutive
subunit HIF-1b/aryl hydrocarbon receptor nuclear translocator. The
HIF heterodimer then binds within the DNA regulatory promoter or
enhancer regions of target genes at speciﬁc locations termed hypoxia
response elements (HREs) and recruits transcriptional coactiva-
tors, p300/CREB-binding protein, to activate transcription.50 The
core HRE consists of the sequence RCGTG (R5 A/G, most often
G) and is surrounded by binding sites for additional transcriptional
factors and coactivators.50
Several links between regulation of HIF stability and iron
homeostasis have been identiﬁed,51 and more recently, HIF-2 has
emerged as an important “local” regulator of intestinal iron absorp-
tion that directly trans-activates the expression of iron transporter
genes in enterocytes29,52,53 (Figure 1). Indeed, mice lacking HIF-2a
in the intestinal epithelium exhibited signiﬁcant decreases in the
duodenal levels of Dmt1, Dcytb and FPN mRNAs, effects that were
not compensated by HIF-1.52 This decrease in the expression of
genes involved in both apical and basolateral iron transport was
associated with a signiﬁcant reduction in plasma and liver iron content,
and a marked decrease in hepatic hepcidin expression, demonstrating
a pivotal role of HIF-2 in steady-state regulation of iron absorption.
Although HIF-2 intestinal knockout mice did not show striking
differences in the morphology of intestinal villi when compared with
control mice, a potential effect of HIF-2 on enterocyte survival,
proliferation, or shedding has not been systematically investigated53,54
Figure 1. HIF-2 transcriptionally regulates the expression of key genes involved in iron transport. Under conditions of iron deficiency, hypoxia, or increased erythropoietic
drive, HIF-2 is stabilized in the duodenal enterocyte and transcriptionally upregulates the expression of DMT11 iron responsive element (IRE), DCYTB, and FPN. This leads to increased
expressionofDMT1andDCYTBat theapical brushbordermembraneandFPNat thebasalmembrane.29,52,53,58 Thedirect bindingofHIF-2 to consensusHREelements in the regulatory
regions of the promoters has been shown for DCYTB and DMT1. At the systemic level, hepatic hepcidin is repressed, preventing its inhibitory action on duodenal iron absorption.
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and remains to be addressed in future studies of the role of HIF-2 in
intestinal function.
The differential target gene speciﬁcity of HIF-2a vs HIF-1a in
the duodenum may be due to interaction of the HIF-a N-terminal
sequence with additional transcription factors, as has previously been
suggested.55 Orthologs of Sp6 transcription factors may possibly act in
cooperation with HIF-2 to increase iron absorption.56 Further, certain
physiological features of the intestinal epithelium may explain the
phenotype of HIF-2a intestinal knockout mice at the basal level. The
gastrointestinal tract has a unique tissue oxygenation proﬁle under
steady-state conditions. While the epithelium is in a relatively hypoxic
state, the subepithelial mucosa is highly vascularized, and meal in-
gestion is known to increase the mucosal blood ﬂow. Reduced blood
ﬂow in the villus microvasculature during the fasting period could thus
result in a relatively hypoxic state of the duodenal enterocytes, which
would stabilize HIF-2a, therefore potentiating the expression ofDMT1
andDCYTB in order to increase apical iron uptake during digestion of a
subsequent meal. Alternatively, other mechanisms could affect local
HIF-2a levels in the duodenal enterocytes, such as intraluminal pH
levels. In human subjects, intraluminal duodenal pH ﬂuctuates from
4.0 duringmeals to below 2.0 during the fasting period. Iron absorption
of inorganic iron is inﬂuenced by pH.6 Given the links between pH
regulation and HIF signaling,57 it is possible that low intraluminal pH
may potentiate HIF-2a stabilization. Additionally, upregulation of
duodenal HIF-2a is likely to occur at the protein level through di-
minished PHD activity in the hypoxic microvilli. Importantly, mice
developing severe anemia and tissue hypoxia in response to
phenyladrazine treatment do not exhibit changes in duodenal HIF-
2a mRNA levels.58 Increased duodenal HIF-2a protein stabiliza-
tion has been shown to mediate the upregulation of Dmt1 and Dcytb
mRNAs in mice fed an iron-deﬁcient diet.52,53 A biphasic regulation
of duodenal FPN has been reported during iron deﬁciency in mice,
in which HIF-2 is essential in the acute regulation of iron export but
dispensable in the chronic phase.29 As iron absorption rates are
higher in younger animals, it is also conceivable that HIF-2 might be
more important during periods of postnatal growth than in adults.
HIF-2 protein levels are also stabilized in other conditions of
high iron demand, such as hypoxia59 or phlebotomy58 (Figure 1).
Altogether, these ﬁndings reveal an important role for HIF-2 in
the iron- and oxygen-dependent regulation of iron absorption.
Posttranscriptional regulation by the IRPs:
a new IRP1/HIF-2 axis
Posttranscriptional regulation of iron homeostasis genes in response
to intracellular iron levels is mediated by IRPs, IRP1 and IRP2,
which bind to IREs found in the 59 or 39 untranslated regions
(UTRs) of target mRNAs.60 IRP1 and IRP2 protein abundance and
IRE-binding activity are regulated by different mechanisms.61 IRP1
does not show detectable IRE-binding activity in the majority of
tissues under physiological conditions, but rather is expressed in the
form of a cytosolic aconitase. By contrast, the protein abundance of
IRP2 is regulated by F-box and leucine-rich repeat protein 5, an
iron- and oxygen-binding hemerythrin domain adaptor protein that
recruits the SKP1–CUL1–F-box E3 ubiquitin ligase complex to
promote IRP2 proteasomal degradation under iron-replete con-
ditions.62 High IRP-binding activity in response to low intracellular
iron levels results in translational repression of mRNAs that contain
an IRE in their 59UTR (such as Fpn, FtH, and FtL) or promotes
mRNA stability if bound to mRNAs that contain an IRE in 39UTR
(as in the case of Dmt1). Dmt1 is present in different isoforms, and
those transcript isoforms that contain an IRE predominate in the
proximal intestine. Although activation of IRPs by iron deﬁciency
would normally be expected to repress translation of FPN, duodenal
FPN levels are increased in iron-deﬁcient animals.15 Importantly,
Zhang et al63 showed that an alternative Fpn mRNA lacking the
59 UTR IRE motif (Fpn-IRE) is preferentially expressed in the
duodenum, which could explain how enterocytes circumvent re-
pression of FPN expression by IRE/IRP machinery. Mice carrying
a deletion for both IRP1 and IRP2 in the intestinal epithelium pre-
sent with decreased DMT1 and transferrin receptor 1 and increased
FtH and FtL protein levels, and they manifest malabsorption and
villus structure disorganization associated with perinatal lethality.64
However, Irp22/2 and Irp12/2 mice are both viable but present
different overt phenotypes. More speciﬁcally, mice with Irp2
deletion in the intestinal epithelium present with iron retention in the
duodenal enterocytes, suggesting that IRP2 plays a cell-autonomous
role in the intestine and also that IRP1 and IRP2 are partly redundant
in the intestine.65, 66 Furthermore, tissue-speciﬁc Irp12/2 and/or
Irp22/2 knockout mouse models have demonstrated that IRP2 is the
major regulator of iron homeostasis in vivo, responding to dietary
iron deﬁciency and hypoxia.60 A 59UTR IRE in the Hif2a mRNA
has been characterized in vitro and may serve as an additional point
of HIF-2 regulation.67 Sanchez et al67 proposed that HIF-2 translation
may be enhanced in the presence of adequate levels of iron. In rats,
hepatic HIF-2a has been shown to be translationally repressed in
response to dietary iron deﬁciency compatible with a role for the
IRE/IRP system in this process.68
Two recent studies have demonstrated that translational regulation
of HIF-2a synthesis by IRP1 in the kidney is critical for controlling
erythropoiesis.69,70 Ghosh et al70 showed that Irp12/2 mice develop
pulmonary hypertension and polycythemia, a phenotype that is
exacerbated in response to an iron-deﬁcient diet and is caused by
excessive EPO production resulting from the absence of translational
repression of Hif-2a mRNA in the kidney. Interestingly, the authors
also showed that secretion of the known HIF target endothelin-1 is
highly upregulated in pulmonary endothelial cells isolated from
Irp12/2 mice compared with controls. Anderson et al69 further
demonstrated that HIF-2 transcriptional activity is increased in the
duodenum of Irp12/2 mice, as indicated by the increased mRNA
expression of Dmt11IRE, Dcytb, and Fpn mRNAs, as well as other
HIF-2 target genes.Moreover, Galy et al71 recently reported that IRPs
regulate apical iron uptake by controlling FPN and DMT1 through
HIF-2. They further showed that IRP deﬁciency in the adult mouse
intestinal epithelium promotes a Ft-mediated “mucosal block.”
As IRP activity is increased in the duodenum in response to iron
deﬁciency,72 it might be hypothesized that Hif-2a is translationally
repressed by IRP1. However, increased HIF-2a protein levels have
been reported in the duodenum of iron-deﬁcient mice.53 A possible
explanation might be that during iron deﬁciency, the effects of IRP1
on Hif-2a mRNA translation are counteracted by the dominant
stabilization of HIF-2a at the protein level, due to the decreased
activities of PHDs (Figure 2). Moreover, IRP1 has been shown to
decrease in hypoxia.73 As the duodenum is hypoxic, even at basal
level, the decrease in IRP1 would amplify the impact of PHD-mediated
regulation of HIF-2a accumulation. By contrast, high intracellular iron
would prevent the translational repression of Hif-2a by IRP1 but
potentially increase the activity of PHDs (Figure 2). However, models
of intestinal iron overload coupled with systemic anemia indicate that
elevated iron levels do not have a pronounced effect on HIF-2 per se
and that systemic anemia/hypoxia is the predominant regulator of
HIF-2.74 It would be interesting to examine these hypotheses more
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speciﬁcally in mice with inducible deletion of Irp1 or Irp2 in the
intestinal epithelium. Further studies addressing these questions may
provide evidence for nonredundant roles of IRPs in the duodenum and
their importance in integrating systemic physiological signals in vivo.
HIF-2: implications for iron-related disorders
Inflammation
Iron absorption is diminished during inﬂammatory conditions. Even-
tually, a decrease in serum iron limits iron availability to erythropoiesis
and contributes to the anemia of inﬂammation (also called anemia of
chronic disease [ACD]).75 Hypoferremia is mainly due to iron
sequestration in macrophages of the reticuloendothelial system.
Hepatic hepcidin expression is markedly induced during infection
and inﬂammation by cytokines (including interleukin [IL] 1 and
IL-6),76 and urinary hepcidin levels are elevated in patients with
chronic inﬂammatory diseases.77 IL-6 signals through binding to the
IL-6 receptor and activates hepcidin transcription by binding of
phosphorylated Signal Transducer and Activator of Transcription
(STAT) to conserved sequence elements in the hepcidin promoter. The
resulting hepcidin elevation is believed to play a major role in the
pathogenesis of ACD.77 These features are reproducible in transgenic
mouse models that overexpress hepcidin78,79 and in mice injected with
the synthetic hepcidin peptide.80 The role of hepcidin in the anemia of
inﬂammation has been detailed elsewhere.75
Inﬂammation also seems to have a direct effect on iron ab-
sorption. Tumor necrosis factor a treatment decreased intestinal iron
absorption both in vitro and in vivo.81,82 In the early inﬂammatory
response, tumor necrosis factor appears to mediate hypoferremia in-
dependently of hepcidin.83 The hepcidin-independent effect of in-
ﬂammation on duodenal iron absorption awaits further investigation.
The mechanisms operating in the intestine to decrease iron ab-
sorption during inﬂammation have been poorly studied at the cellular
level. Importantly, HIF-1a has been shown to play a crucial role in
the regulation of epithelial barrier function of the mucosa in mouse
models characterized by intestinal inﬂammation.84 However, the role
of HIF-2a during intestinal inﬂammation has not yet been addressed.
Interestingly, nitric oxide (NO), an important mediator of inﬂamma-
tion, has been shown to stimulate the IRE-binding activity of IRP1 in
macrophages.85 Although this mechanism has not been validated in
enterocytes, it is possible that NO–mediated translational repression of
HIF-2 could contribute to the ability of inﬂammation to decrease in
iron absorption.
Polycythemia/ineffective erythropoiesis
Erythrocytosis is caused by an exacerbated proliferation of erythrocyte
progenitors in the bone marrow leading to an absolute increase in
circulating red cell mass. Individuals who are exposed to high-altitude
hypoxia develop erythrocytosis and an accompanying increase in iron
absorption when compared with native residents of high altitude or to
individuals living at sea level.86 Interestingly, HIF-2a and PHD2
polymorphisms are present at high frequencies in human populations
living in the Tibetan or Andean plateaus and are associated with lower
values of hemoglobin than in individuals living in other altitudes.87,88
This implies a selective advantage in these individuals in comparison
with normal individuals developing polycythemia in high altitudes.
Figure 2. Schematic of HIF-2 regulation in response to cellular iron deficiency and overload in duodenal enterocytes. When cytosolic iron levels are elevated, IRP1
incorporates an iron-sulfur cluster, which interferes with the ability of IRP1 to bind IRE. This promotes translation of HIF-2 mRNA but also increases the degradation of HIF-2
mediated by the PHDs. When cytosolic iron levels are low, IRP1 binds to IRE in the 59-UTR of HIF-2 mRNA, blocking HIF-2 translation. However, decreased activity of PHDs
prevents the degradation of HIF-2 by the proteasome.
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Increased but defective production of erythroblasts in the bone
marrow, a process known as ineffective erythropoieis, is a hallmark
of b-thalassemia and other dyserythropoietic anemias.89 b-thalasse-
mic patients andmousemodels present inappropriately low expression
of hepcidin relative to hepatic iron stores and high iron absorption
rates.90 Themolecular mechanism(s) bywhich the erythropoietic drive
promotes hepcidin suppression during normal and stress erythropoi-
esis has not been fully elucidated so far. Possible regulators of hepcidin
expression that have been proposed include changes in transferrin
saturation, increased release of soluble molecules like growth dif-
ferentiation factor 15 and twisted gastrulation homolog 1 from
erythroblasts, and a direct effect of EPO on hepatocytes.91 Whether
growth differentiation factor 15 or twisted gastrulation homolog 1 are
upregulated in the gut in these conditions and whether they directly
regulate iron absorption has not been examined.
Transfusion and pharmacologic chelation are the current treat-
ments for patients with iron-loading anemias. However, both in-
creased iron absorption and repetitive transfusions contribute to the
massive organ iron load that leads to lethal complications. Anderson
et al58 recently showed that intestinal HIF-2 is essential for efﬁcient
erythropoiesis. It would be of interest to explore whether intestinal
HIF-2 contributes to iron absorption and iron overload observed in
b-thalassemic patients.
Hereditary hemochromatosis
HH is an autosomal recessive genetic disorder characterized by
iron overload in the liver and other parenchyma. HH is caused by
mutations in genes encoding signaling molecules that regulate
hepcidin expression in response to iron, namely, HFE, TfR2, and
HFE2, or mutations in the hepcidin gene (HAMP) itself. The age
of onset and clinical phenotype varies depending on the particular
gene that is mutated.92 Another hereditary iron overload disorder
(termed FPN disease) is caused by autosomal dominant mutations in
the FPN gene that impair hepcidin binding or alter FPN localization.93
In regard to HFE-associated HH, different mutations have been
identiﬁed; however, their penetrance is variable, and HFE homo-
zygotes show phenotypic heterogeneity that ranges from complete
absence of disease to severe iron overload in liver and pancreas lead-
ing to complications such as hepatic steatosis, hepatocellular carci-
noma, and diabetes. As previously mentioned, the HIF-2 transcription
factor is crucial for the regulation of iron homeostasis by regulating the
expression of DMT1 and DCYTB in the duodenum.52 Moreover,
HIF-2a stabilization in the intestinal epithelium is sufﬁcient to augment
expression levels of DMT1, DCYTB, and FPN and leads to hepatic
iron overload.29,53 As previously mentioned, high expression levels of
duodenal Dmt1, Dcytb, and Fpn mRNA correlate with high iron
absorption rates in various models characterized by low hepcidin
expression. Importantly, deletion of intestinal Hif-2a in hepcidin
knockout mice alleviates iron overload in the liver and pancreas by
decreasing the expression of the duodenal DMT1, DCYTB, and
FPN.54 These ﬁndings highlight the importance of HIF-2 in the
transcriptional upregulation of genes involved in iron absorption in the
context of hepcidin deﬁciency and suggest that HIF-2 could contribute
to chronic iron accumulation in humans with HH. Recently, we
showed that hepatic HIF-2a is dispensable for the homeostatic
response to iron deﬁciency, but genetic stabilization of HIF-2a
due to hepatic loss of VHL mediates a radical decrease in hepcidin
expression that occurs in response to increased erythropoietic activity.54
Moreover, hepaticHIF-2a stabilization in the context ofVHLdeﬁciency
leads to the development of hepatic steatosis and highly angiogenic
tumors in mice.94 It has been previously proposed that DMT195 and
DCYTB,96 2 HIF-2 target genes, could act as genetic modiﬁers in HFE
hemochromatosis. Therefore, whether polymorphic variation in HIF-2a
itself contributes to the phenotypic heterogeneity of HFE-related hemo-
chromatosis patients developing severe clinical features (steatosis and
cancer) vs milder phenotypes would be of interest.
Potential of the use of HIF-2 modulators in the treatment of
iron-related diseases
Although the role of HIF-2 in the pathogenesis of HFE or other forms
of hemochromatosis in humans remains to be established, the
previously discussed ﬁndings provide proof of concept that HIF-2
inhibitors could be employed therapeutically in patients with HH in
combination with conventional phlebotomy. Increased iron absorp-
tion is also believed to contribute to iron loading in thalassemias
and sideroblastic anemia, in addition to that caused by successive
blood transfusions.90 Therefore, HIF-2 inhibitors might also prove
beneﬁcial for these patients by inhibiting both inefﬁcient erythro-
poiesis and iron absorption. Currently, 1 study has identiﬁed a class
of chemical compounds that inhibit HIF-2a translation by an IRP1-
dependent mechanism,97 but the pharmacokinetic properties and
inhibitory potential of these compounds in vivo have not yet been
determined. The recent demonstration of the critical role of the
IRP–HIF-2 axis in intestinal iron absorption69,70 may encourage the
evaluation of these HIF-2 inhibitors in vivo.
Finally, prolyl-hydroxylase inhibitors (PHIs) represent a promising
potential alternative treatment for anemia.98,99 PHIs might be
particularly advantageous in patients with anemia of renal failure,
who are currently treated with intravenous/subcutaneous injections of
recombinant EPO or related erythropoiesis-stimulating agents. PHIs
improved hematologic parameters in a mouse model of chronic renal
insufﬁciency by inducing hepatic Epo expression.100 However, the
safety proﬁle of PHIs and their ultimate efﬁcacy in inducing the
stabilization of both HIF-1 and HIF-2 in patients remain to be
determined. Given the dual roles of HIF-2 in the regulation of iron
absorption and EPO expression, PHIs or other compounds that spe-
ciﬁcally stabilize HIF-2 may represent possible therapeutic strategies
for patients with iron-deﬁciency anemia or ACD.
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